ARKK Holdings of Intellia Therapeutics (NTLA) - Updated Daily
Gene TherapyGenomicsSynthetic BiologyGene Base EditingCRSPR Gene Editing
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 3.38% | $3.56b |
| 🏋🏿♂️Weight Rank In ARKK | 🌏Country |
| 15 | 🇺🇸United States |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 15 | $62.04 |
| 🎫ARK Ownership Percent | |
| 7.84% | |
| Description | |
|---|---|
| intellia therapeutic’s core mission is to develop curative medicines, utilizing the promise of the crispr/cas9 gene editing technology. the development of crispr/cas9 gene editing technology opens a new frontier in biomedical research and clinical intervention. adapted from a natural cellular process, crispr/cas9 permits the editing of any gene in any organism with unprecedented simplicity and flexibility. the incredible potential of this technology for treating human genetic disease inspired a group of life science veterans to create intellia therapeutics. intellia was founded in 2014 by caribou biosciences and atlas venture, along with a consortium of scientists who have helped define the space. intellia therapeutics holds exclusive access to a broad intellectual property portfolio covering the application of crispr/cas9 technology for human therapeutic use. intellia has built an experienced team of individuals to meet the challenges of bringing crispr/cas9 therapeutics to the | |
| Website | |
| intelliatx.com |
Other ETFs That Hold NTLA
Research Notes and Commentary for NTLA
No Research Notes Found for NTLA